Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Recruiting

Phase 2

Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

Sponsor:

Academic and Community Cancer Research United

Code:

NCT04626791

Conditions

Mantle Cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Acalabrutinib

Bortezomib

Cyclophosphamide

Cytarabine

Doxorubicin Hydrochloride

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-07. This information was provided to ClinicalTrials.gov by Academic and Community Cancer Research United on 2024-03-12.